Research Updates

Never miss an important update! Get our latest research updates delivered right to your email inbox.

Crohn's & Colitis Foundation Receives $5 Million Research Donation from Litwin IBD Pioneers Initiative

We are pleased to announce that the Crohn’s & Colitis Foundation recently received a donation of $5 million from the Litwin Family. The Litwin IBD Pioneers Initiative, formerly the Broad Medical Research Program, supports researchers throughout the world by funding highly innovative pilot IBD research studies that focus on improving IBD management, including developing new diagnostic and treatment options, predicting clinically relevant disease subsets and identifying noninvasive markers of disease activity of Crohn’s disease and ulcerative colitis.

Read More »

New Diet Study Highlights Potential Benefits of AIP Diet for IBD Patients

As Thanksgiving approaches, we understand that many of our patients may be thinking about the foods they may want to avoid this holiday season. Thankfully, researchers across the country have been working to better understand the role certain diets can play in the management of IBD. Last month, we blogged about Dr. Lewis’ clinical trial comparing a standard carbohydrate diet (SCD) with a Mediterranean diet. This month, we are highlighting a small study, featured in IBD News Today, which looks at the efficacy of an autoimmune protocol diet (AIP diet).

Read More »

Results from Celgene Phase 2 Studies of Oral Ozanimod in Crohn's Disease and Ulcerative Colitis Presented at World Congress of Gastroenterology at ACG2017

Celgene announced this week that phase 2 data of investigational compound ozanimod in Crohn's disease and ulcerative colitis will be presented at the World Congress of Gastroenterology at ACG2017 (WCOG at ACG2017) in Orlando. The studies include new data from the STEPSTONE study in patients with moderately to severely active Crohn's disease (CD) and long-term data from the open-label extension of the TOUCHSTONE study in patients with moderately to severely active ulcerative colitis (UC). Ozanimod is an investigational, selective sphingosine 1-phosphate (S1P) 1 and 5 receptor modulator.

Read More »

New Diet and IBD Study Begins Recruiting Patients

New Diet and IBD Study Begins Recruiting Patients

October 11, 2017
Posted by: Clinical Trials Community

Blog type

There has been a lot of buzz throughout the IBD Community about the role diet plays in the management of IBD. This month, we are highlighting Dr. James D. Lewis’s study, which received funding to determine if the specific carbohydrate diet (SCD) is superior to the Mediterranean-style diet (MSD) for patients with active Crohn’s disease.

Read More »

Kenneth Rainin Foundation Launches New Resource to Inspire Collaboration in IBD Research

In order to have a positive impact in IBD, it is critical that foundations work together to fund the many different types of research needed to advance the field towards potential cures. That’s why we are excited that our colleagues at the Kenneth Rainin Foundation have launched an online resource to inspire collaboration in Inflammatory Bowel Disease research.

Read More »

Data and Safety Monitoring Board (DSMB) unanimously recommends RedHill's Phase 3 MAP US Study continue as planned

The independent Data and Safety Monitoring Board (DSMB) has reviewed safety and efficacy data from the first 222 patients enrolled in RedHill's Phase III Map US study who have completed 26 weeks of assessment and unanimously recommended the study continue as planned.

Read More »

Seres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis: Study results expected in the second half of 2017

Earlier last month, Seres Therapeutics, Inc. announced that it has completed enrollment for its ongoing SER-287 Phase 1b clinical study of 58 patients suffering from mild-to-moderate ulcerative colitis who are failing current therapies. Enrollment in this trial is especially noteworthy as the SER-287 study is the first microbiome therapeutic candidate to reach clinical‐stage development in a chronic inflammatory disease, and the first in an indication outside of infectious disease.

Read More »

Pediatric RISK Stratification Study Results

Pediatric RISK Stratification Study Results

July 20, 2017
Posted by: Clinical Trials Community

Blog type

The Crohn’s & Colitis Foundation’s “RISK Stratification” study is the largest new-onset study completed on pediatric Crohn’s disease patients. In early 2017, researchers successfully identified biological signatures in pediatric patients with newly diagnosed Crohn’s disease capable of predicting whether a child will develop disease-related complications requiring major surgery within three to five years.

Read More »

Welcome to the Foundation’s New Clinical Trials Community!

Welcome to the Foundation’s New Clinical Trials Community!

July 19, 2017
Posted by: Courtney Bisbee, MPH

Blog type

We are glad that you stopped by and hope that you take some time to check out all of the new resources created as part of this initiative. Our Community was created to help raise awareness of IBD clinical trials happening all over the country and to educate patients, caregivers, and physicians about the value of participating in clinical research. As many of you may already know, by participating in IBD clinical trials, patients and physicians help accelerate the development of new treatment options for the IBD community. And because IBD is so specific to each individual patient, having a number of treatment options available to the patient is a key component to successfully managing the disease.

Read More »